title: Nanofacilitated synergistic treatment for rheumatoid arthritis: A 'three-pronged' approach.
abstract: Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease of unidentified etiology that affects the joints and causes pain, swelling, stiffness and redness in the joints. The exact cause of rheumatoid arthritis has not yet been discovered and, consequently, treatment methods have not been optimally effective. It has long been treated with anti-inflammatory and immunosupressants including modern biologics either alone or in combination but all of the drugs have severe life threatening consequences with impaired immune function due to nonspecific targeting. Therefore, a three-pronged approach of local, active and synergistic targeting can be used to optimize delivery of therapeutic agents to reduce toxicity and patient outcome without compromising patient's immunity.
authors.affiliation: Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110 062, India.
authors.forename: Shweta
authors.initials: S
authors.lastname: Pandey
authors.affiliation: Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110 007, India.
authors.forename: Nishant
authors.initials: N
authors.lastname: Rai
authors.affiliation: Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110 062, India.
authors.forename: Purnima
authors.initials: P
authors.lastname: Rawat
authors.affiliation: Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110 062, India.
authors.forename: Farhan Jalees
authors.initials: FJ
authors.lastname: Ahmad
authors.affiliation: Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110 062, India. Electronic address: stalegaonkar@gmail.com.
authors.forename: Sushama
authors.initials: S
authors.lastname: Talegaonkar
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use; D049109:Cell Proliferation; D004337:Drug Carriers; D006801:Humans; D007107:Immune System; D007109:Immunity; D007155:Immunologic Factors / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy; D050997:Nanomedicine / Q000379:methods*
chemical_list: D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D001688:Biological Products; D004337:Drug Carriers; D007155:Immunologic Factors